Loperamide 2 Mg Capsules
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Loperamide 2 mg Capsules
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each capsule contains 2 mg Loperamide Hydrochloride.
Excipient(s) with known effect:
This product contains lactose monohydrate
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Capsule, hard
Green and dark grey, size 4 capsules containing a fine white powder. Printed 'LOP2'.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Loperamide hydrochloride is indicated for the symptomatic treatment of acute diarrhoea of any aetiology including acute exacerbations of chronic diarrhoea for periods of up to 5 days, in adults and children over 8 years. Loperamide hydrochloride is also indicated for the symptomatic treatment of chronic diarrhoea in adults.
4.2. Posology and method of administration
For oral administration.
The capsules should be taken with liquid.
Acute diarrhoea
Adults and Children 8-17 years
The initial dose is 2 capsules (4 mg) for adults and 1 capsule (2 mg) for children; followed by 1 capsule (2 mg) after every subsequent loose stool.
The maximum dose is 8 capsules (16 mg) daily for adults; in children it must be related to the body weight (3 capsules/20 kg) but should not exceed a maximum of 8 capsules per day.
Chronic Diarrhoea
Adults
The initial dose is 2 capsules (4 mg) daily; this initial dose should be adjusted until 1-2 solid stools a day are obtained, which is usually achieved with a maintenance dose of 1-6 capsules (2 mg-12 mg) daily.
Tolerance has not been observed and therefore subsequent dosage adjustment should be unnecessary.
The maximum dose is 8 capsules (16 mg) daily.
Paediatric Populations Children 2-8 years
The capsule form of loperamide is not recommended in children of this age. A syrup is commercially available.
Children Under 2 Years
Loperamide HCl should not be used in children under 2 years of age.
Elderly
No dose adjustment is required for the elderly.
Renal Impairment
No dose adjustment is required for patients with renal impairment.
Hepatic Impairment
Although no pharmacokinetic data are available in patients with hepatic impairment loperamide HCl should be used with caution in such patients because of reduced first pass metabolism (see Section 4.4).
4.3 Contraindications
• Loperamide HCl is contraindicated in patients with a known hypersensitivity to loperamide HCl or to any of the excipients listed in section 6.1.
• Loperamide HCl should not be used in children under 2 years of age.
• Loperamide HCl should not be used as the primary therapy:
• in patients with acute dysentery, which is characterised by blood in stools and high fever,
• in patients with acute ulcerative colitis,
• in patients with bacterial enterocolitis caused by invasive organisms including Salmonella, Shigella, and Campylobacter,
• in patients with pseudomembranous colitis associated with the use of broad-spectrum antibiotics.
Loperamide HCl should not be used if inhibition of peristalsis is to be avoided due to the possible risk of significant sequelae including ileus, megacolon, toxic megacolon, constipation, abdominal distension particularly in severely dehydrated children, acute ulcerative colitis or pseudomembranous colitis associated with broad spectrum antibiotics. Loperamide HCl must be discontinued promptly when constipation, abdominal distension or ileus develop.
4.4 Special warnings and precautions for use
Treatment of diarrhoea with loperamide HCl is only symptomatic. Whenever an underlying etiology can be determined, specific treatment should be given when appropriate.
In patients with diarrhoea, especially in children, fluid and electrolyte depletion may occur. The use of loperamide HCl does not preclude the need for appropriate fluid and electrolyte replacement therapy, which is essential in such patients. Loperamide HCl should not be given to children aged 2 to 6 years without medical prescription and supervision.
Since persistent diarrhoea can be an indicator of potentially more serious conditions, loperamide hydrochloride should not be used for prolonged periods until the underlying cause of the diarrhoea has been investigated.
In acute diarrhoea, if clinical improvement is not observed within 48 hours, the administration of loperamide HCl should be discontinued and patients should be advised to consult their physician.
Patients with AIDS treated with loperamide HCl for diarrhoea should have therapy stopped at the earliest signs of abdominal distension. There have been isolated reports of obstipation with an increased risk for toxic megacolon in AIDS patients with infectious colitis from both viral and bacterial pathogens treated with loperamide
HCl.
Although no pharmacokinetic data are available in patients with hepatic impairment, loperamide HCl should be used with caution in such patients because of reduced first pass metabolism. Patients with hepatic dysfunction should be monitored closely for signs of central nervous system (CNS) toxicity.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose- galactose malabsorption should not take Loperamide capsules.
4.5 Interaction with other medicinal products and other forms of interaction
Non-clinical data have shown that loperamide is a P-glycoprotein substrate.
Concomitant administration of loperamide (16 mg single dose) with quinidine, or ritonavir, which are both P-glycoprotein inhibitors, resulted in a 2 to 3-fold increase in loperamide plasma levels. The clinical relevance of this pharmacokinetic interaction with P-glycoprotein inhibitors, when loperamide is given at recommended dosages, is unknown.
The concomitant administration of loperamide (4 mg single dose) and itraconazole, an inhibitor of CYP3A4 and P-glycoprotein, resulted in a 3 to 4-fold increase in loperamide plasma concentrations. In the same study a CYP2C8 inhibitor, gemfibrozil, increased loperamide by approximately 2-fold. The combination of itraconazole and gemfibrozil resulted in a 4-fold increase in peak plasma levels of loperamide and a 13-fold increase in total plasma exposure. These increases were not associated with central nervous system (CNS) effects as measured by psychomotor tests (i.e., subjective drowsiness and the Digit Symbol Substitution Test).
The concomitant administration of loperamide (16 mg single dose) and ketoconazole, an inhibitor of CYP3A4 and P-glycoprotein, resulted in a 5-fold increase in loperamide plasma concentrations. This increase was not associated with increased pharmacodynamic effects as measured by pupillometry.
Concomitant treatment with oral desmopressin resulted in a 3-fold increase of desmopressin plasma concentrations, presumably due to slower gastrointestinal motility.
It is expected that drugs with similar pharmacological properties may potentiate loperamide’s effect and that drugs that accelerate gastrointestinal transit may decrease its effect.
4.6 Fertility, pregnancy and lactation
Pregnancy
Although there are no indications that loperamide HCl possesses teratogenic or embryotoxic properties, the anticipated therapeutic benefits should be weighed against potential hazards before loperamide HCl is given during pregnancy, especially during the first trimester.
Breastfeeding
Small amounts of loperamide may appear in human breast milk. Therefore, loperamide HCl is not recommended during breast-feeding.
4.7 Effects on ability to drive and use machines
Tiredness, dizziness, or drowsiness may occur in the setting of diarrhoeal syndromes treated with loperamide HCl. Therefore, it is advisable to use caution when driving a car or operating machinery.
4.8 Undesirable effects
Adults and children aged >12 years
The safety of loperamide HCl was evaluated in 3076 adults and children aged >12 years who participated in 31 controlled and uncontrolled clinical trials of loperamide HCl used for the treatment of diarrhoea. Of these, 26 trials were in acute diarrhoea (N=2755) and 5 trials were in chronic diarrhoea (N=321).
The most commonly reported (i.e., >1% incidence) adverse drug reactions (ADRs) in clinical trials with loperamide HCl in acute diarrhoea were: constipation (2.7%), flatulence (1.7%), headache (1.2%) and nausea (1.1%). In clinical trials in chronic diarrhoea, the most commonly reported (i.e., >1% incidence) ADRs were: flatulence (2.8%), constipation (2.2%), nausea (1.2%) and dizziness (1.2%).
List of adverse reactions
The data in Table 1 represent the results from 3076 adults and children aged >12 years of age who participated in 31 controlled and uncontrolled clinical trials of loperamide HCl used for the treatment of diarrhoea. Of these, 26 trials were in acute diarrhoea (N=2755) and 5 trials were in chronic diarrhoea (N=321).
The frequency categories use the following convention: very common (>1/10); common (>1/100 to <1/10); uncommon (>1/1,000 to <1/100); rare (>1/10,000 to <1/1,000); and very rare (<1/10,000).
Table 1: : Frequency of ADRs Reported with the Use of Loperamide HCl from Clinical
Trials in Adults and Children Aged > 12 Years of Age
|
System Organ Class |
Indication | |
|
Acute Diarrhoea (N=2755) |
Chronic Diarrhoea (N=321) | |
|
Nervous system disorders | ||
|
Headache |
Common |
Uncommon |
|
Dizziness |
Uncommon |
Common |
|
Gastrointestinal disorders | ||
|
Constipation, nausea, flatulence |
Common |
Common |
|
Abdominal pain, abdominal discomfort, dry mouth |
Uncommon |
Uncommon |
|
Abdominal pain upper, vomiting |
Uncommon | |
|
Dyspepsia |
Uncommon | |
|
Abdominal distension |
Rare | |
|
Skin and subcutaneous tissue disorders | ||
|
Rash |
Uncommon | |
Post-Marketing ADR Data
The process for determining post-marketing ADRs for loperamide HCl did not differentiate between chronic and acute diarrhoea indications or differentiate between adults or children; therefore, the ADRs listed below represents the combined indications and subject populations. The ADRs identified during post-marketing for loperamide HCl are listed below by System Organ Class and Medical Dictionary for Regulatory Activities (MedDRA) Preferred Term (PT):
Immune system disorders:
Hypersensitivity reaction, anaphylactic reaction (including anaphylactic shock), and anaphylactoid reaction
Nervous system disorders:
Somnolence, loss of consciousness, stupor, depressed level of consciousness, hypertonia, and coordination abnormality
Eye disorders: Miosis
Gastrointestinal disorders:
Ileus (including paralytic ileus), megacolon (including toxic megacolon), and glossodynia
Skin and subcutaneous tissue disorders:
Bullous eruption (including Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme), angioedema, urticaria, and pruritus
Renal and urinary disorder: Urinary retention
General disorders and administration site conditions: Fatigue
Paediatric population
The safety of loperamide HCl was evaluated in 607 patients aged 10 days to 13 years who participated in 13 controlled and uncontrolled clinical trials of loperamide HCl used for the treatment of acute diarrhoea. In general, the ADR profile in this patient population was similar to that seen in clinical trials of loperamide HCl in adults and children aged 12 years and over.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
4.9 Overdose
Symptoms
In case of overdosage (including relative overdose due to hepatic dysfunction), CNS depression (stupor, coordination abnormality, somnolence, miosis, muscular hypertonia, and respiratory depression), constipation, urinary retention and ileus may occur. Children may be more sensitive to CNS effects than adults.
Treatment
Treatment is symptomatic and supportive. In patients who have not vomited, gastric lavage should precede the administration of activated charcoal. If symptoms of overdose occur, naloxone can be given as an antidote. Since the duration of action of loperamide is longer than that of naloxone (1 to 3 hours), repeated treatment with naloxone might be indicated. Therefore, the patient should be monitored closely for at least 48 hours in order to detect possible CNS depression.
Children and patients with hepatic dysfunction may be more sensitive to the central nervous system effects. Neither forced diuresis nor haemodialysis is expected to be effective.
5.1 Pharmacodynamic properties
ATC Code: A07DA03 Antipropulsives.
Loperamide hydrochloride binds to the opiate receptor in the gut reducing propulsive peristalsis, increasing intestinal transit time. Loperamide hydrochloride increases the tone of the anal sphincter.
In a double blind randomised clinical trial in 56 patients with acute diarrhoea receiving loperamide, onset of anti-diarrhoeal action was observed within one hour following a single 4 mg dose. Clinical comparisons with other antidiarrhoeal drugs confirmed this exceptionally rapid onset of action of loperamide hydrochloride.
5.2 Pharmacokinetic properties
The half-life of loperamide hydrochloride in man is 10.8 hours with a range of 9-14 hours. Studies on distribution in rats show high affinity for the gut wall with preference for binding to the receptors in the longitudinal muscle layer. Loperamide is well absorbed from the gut, but is almost completely extracted and metabolised by the liver where it is conjugated and excreted via the bile. Due to its high affinity for the gut wall and its high first pass metabolism, very little loperamide reaches the systemic circulation.
5.3 Preclinical safety data
Preclinical information has not been included because the safety profile of loperamide hydrochloride has been established after many years of clinical use. Please refer to section 4.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Capsules contain:
Maize starch Lactose monohydrate Povidone (E1201)
Sodium starch glycolate (Type A)
Magnesium Stearate (E572)
The capsule shell contains: Gelatin
Patent blue V (E131) Titanium dioxide (E171) Yellow iron oxide (E172).
The printing ink contains:
Shellac
Simeticone
Titanium dioxide (E171) Propylene glycol (E1520).
6.2 Incompatibilities
Not applicable
6.3 Shelf life
3 years.
6.4 Special precautions for storage
This medicinal product does not require any special storage conditions.
6.5 Nature and contents of container
HDPE containers with LDPE lids or polypropylene containers with polyethylene lids in packs of 100, 250 and 500 capsules.
PVdC coated PVC film with hard temper aluminium foil strips in packs of 30 capsules.
Not all pack sizes may be marketed.
6.6 Special precautions for disposal
No special requirements for disposal.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
7 MARKETING AUTHORISATION HOLDER
Teva UK Limited Brampton Road Hampden Park Eastbourne East Sussex BN22 9AG
8 MARKETING AUTHORISATION NUMBER(S)
PL 00289/1980
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
08/07/2016
10 DATE OF REVISION OF THE TEXT
08/07/2016